Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
| ▸ | NEK2 | P51955 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19421193 | 1.00 | MEN1 (0.44) | MEN1KMT2AALDH1A1MAPTJAK3 | |
| SCHEMBL15804820 | 0.78 | KMT2A (0.35) | MEN1KMT2AMAPTNEK2 | |
| SCHEMBL17813269 | 0.78 | KMT2A (0.35) | MEN1KMT2AMAPTNEK2 | |
| SCHEMBL15804805 | 0.78 | KMT2A (0.35) | MEN1KMT2AMAPTNEK2 | |
| SCHEMBL21882563 | 0.77 | ALDH1A1 (0.53) | MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL15156427 | 0.77 | CTSK (0.34) | MEN1KMT2AALDH1A1MAPTJAK3 | |
| SCHEMBL15156424 | 0.77 | CTSK (0.34) | MEN1KMT2AALDH1A1MAPTJAK3 | |
| SCHEMBL15156426 | 0.77 | CTSK (0.34) | MEN1KMT2AALDH1A1MAPTJAK3 | |
| SCHEMBL11102084 | 0.75 | EGFR (0.37) | ALDH1A1 | |
| SCHEMBL15156069 | 0.75 | EGFR (0.37) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10822348-B2 | Inhibitors of Bruton's tyrosine kinase and methods of their use | JANSSEN PHARMACEUTICA NV (BE) | 2020-11-03 | — | — | US | disclosed |
| US-10800792-B2 | Inhibitors of Bruton's tyrosine kinase and method of their use | JANSSEN PHARMACEUTICA NV (BE) | 2020-10-13 | — | — | US | disclosed |
| US-10689396-B2 | Inhibitors of Bruton's tyrosine kinase and methods of their use | JANSSEN PHARMACEUTICA NV (BE) | 2020-06-23 | — | — | US | disclosed |
| US-20190284204-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2019-09-19 | — | — | US | disclosed |
| US-20190284203-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2019-09-19 | — | — | US | disclosed |
| US-10323037-B2 | Aminopyridazinone compounds as protein kinase inhibitors | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2019-06-18 | — | — | US | disclosed |
| US-9951077-B2 | Aminopyridazinone compounds as protein kinase inhibitors | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2018-04-24 | — | — | US | disclosed |
| US-20170283431-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2017-10-05 | — | — | US | disclosed |
| US-20170283431-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2017-10-05 | — | — | US | disclosed |
| US-20170152264-A1 | AMINOPYRIDAZINONE COMPOUNDS AS PROTEIN KINASE INHIBITORS | Eternity Bioscience Inc. (US) | 2017-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10689396-B2 | Inhibitors of Bruton's tyrosine kinase and methods of their use | ABL1, BTK, MYLK2 | MEN1 2461/4885KMT2A 2564/4885ALDH1A1 3899/4885 |
| US-20190284204-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE | ABL1, BTK, MYLK2 | MEN1 2551/4885KMT2A 2626/4885ALDH1A1 4003/4885 |
| US-20170152264-A1 | AMINOPYRIDAZINONE COMPOUNDS AS PROTEIN KINASE INHIBITORS | SSB, MAPKAPK5, BCL9 | MEN1 2621/4885KMT2A 1083/4885ALDH1A1 3332/4885 |
| US-10822348-B2 | Inhibitors of Bruton's tyrosine kinase and methods of their use | ABL1, BTK, MYLK2 | MEN1 2461/4885KMT2A 2564/4885ALDH1A1 3899/4885 |
| US-20170283431-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE | ABL1, BTK, MYLK2 | MEN1 2551/4885KMT2A 2626/4885ALDH1A1 4003/4885 |
| US-20190284203-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE | ABL1, BTK, MYLK2 | MEN1 2551/4885KMT2A 2626/4885ALDH1A1 4003/4885 |
| US-10323037-B2 | Aminopyridazinone compounds as protein kinase inhibitors | SSB, MAPKAPK5, BCL9 | MEN1 2621/4885KMT2A 1083/4885ALDH1A1 3332/4885 |
| US-10800792-B2 | Inhibitors of Bruton's tyrosine kinase and method of their use | ABL1, BTK, MYLK2 | MEN1 2551/4885KMT2A 2626/4885ALDH1A1 4003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.